SMM Global – Stock Market Manager Stock Market Manager simplifies distribution and disclosure of press releases, research and corporate news to financial terminals, print, broadcast and trade media, wire services, news agencies, databases, portals and websites.
Weekly Update: May 8th, 2023
Black Swan Connection Newsletter Signup
Breaking News
On Saturday the annual shareholders meeting for Berkshire Hathaway didn’t disappoint and especially not the BRK.A shareholders. If there was ever a case for saying, I’m not going through the brain damage of picking stocks, you can just use some dollar cost averaging and buy BRK.A on the dips and you’ll do better than 90% of the investors out there.
Berkshire Hathaway’s portfolio’s five largest positions are in Apple Inc. (AAPL), Bank of America Corp (BAC), Chevron (CVX), The Coca-Cola Company (KO), and American Express Company (AXP).
Warren Buffett is undeniably the most famous and influential investor in modern history, based on his extraordinary performance record. Not surprisingly, the investment portfolio of Berkshire Hathaway Inc. (BRK.A), the holding company employing the Oracle of Omaha as chairman and CEO, receives wide media attention and scrutiny, even though Buffett is no longer making every investment decision. A look at Warren Buffett’s long-term track record explains the smiling faces in Omaha Saturday, many of them were made millionaires by the investing guru’s astute moves and patient value philosophy over the years.
Berkshire Hathaway’s compounded annual gain was 19.8% from 1965 through the end of last year, compared with 9.9% for the S&P 500. That’s an overall total return of 3,787,464% vs. 24,708% for the benchmark.
Corporate News
The 21st Century Investment Bank Capital Raises + Strategic Advisory
Donald Capital is a boutique Investment Bank that focuses on raising capital for emerging growth companies in the U.S. and around the globe.
Ideally, we like to work with Private and Public companies with a good management team, a compelling business plan, and the ability to gain market share.
For more information go to: www.DonaldCapital-NY.com
4-19-2023 Can B Corp. (OTC CANB)
Reports Growth of 45% to Company All-Time High $6.7 Million Annual Revenue
Led by Significant Increase in Duramed
Adjusted EBITDA Loss Decreased by 25% to $2.1 Million
HICKSVILLE, NY, April 19, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Can B Corp. (OTCQB: CANB) (“Can B” or the “Company”), a health and wellness company specializing in developing, producing, and selling hemp-derived cannabinoid products, today announced the Company’s financial results for the twelve months ended December 31, 2022.
Key Financial Highlights for 2022
- Revenue increased 45% to $6.7 million.
- Gross profit decreased 13% to $2.6 million.
- Gross margin decreased to 39.1%, due to a higher revenue percentage mix from Duramed.
- Adjusted EBITDA loss decreased by 25% to $2.1 million.
- Accounts receivable at $6.6 million.
- Inventory at $2.0 million.
- Total assets at $15.6 million.
- Total stockholders’ equity at $2.7 million.
Coeptis Therapeutics Holdings, Inc. NASDAQ (COEP)
Coeptis Therapeutics Signs Agreement to Acquire Allogeneic Immuno-Oncology NK Platform in Phase 1 Clinical Trials from Deverra Therapeutics
Proposed transaction would provide Coeptis with two clinical stage assets leveraging NK cell therapies in relapsed or refractory acute myeloid leukemia (AML) and hospitalized respiratory infections, as well as preclinical programs for hematologic and solid tumors
Clinical data from AML Clinical Trial Expected during 2H 2023
WEXFORD, Pa. , April 18, 2023 /PRNewswire/ — Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (“Coeptis” or “the Company”), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced it has entered into a binding term sheet with Deverra Therapeutics, Inc. (“Deverra Therapeutics”) pursuant to which it has obtained an exclusive right, until August 31, 2023, to negotiate towards the acquisition or license of assets from Deverra Therapeutics related to its proprietary allogeneic stem cell expansion and directed differentiation platform for the generation of multiple distinct immune effector cell types, including natural killer (NK) and monocyte/macrophages. Deverra Therapeutics is currently advancing clinical programs investigating these technologies in relapsed/refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) and patients hospitalized with respiratory viral infections.
3-15-2023 Can B Corp. (OTC CANB)
Can B Corp. Completes Corporate Debt Restructuring to Position for Uplisting to National Securities Exchange
HICKSVILLE, NY, March 15, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Can B Corp. (OTCQB: CANB) (“Can B” or the “Company”), a health and wellness company specializing in developing, producing, and selling hemp-derived cannabinoid products and durable medical devices, is pleased to announce it has successfully completed a corporate debt restructuring.
Through the restructuring, Can B raised $1.55 million of new capital and extended previously due notes payable totaling $7.0 million to September 1, 2023, and December 31, 2024. Specifically, three Promissory Notes issued to three funds in early 2022 and three Promissory Notes issued to three private investors in late 2022 were restructured to extend maturity dates to late in 2023 to give the Company an additional window to deploy the capital from the new raise.
3-6-2023 International Food and Beverage (OTC IFBC)
See the latest investor package. Dino is really getting traction.
2-15-2023 Antibe Therapeutics, Inc. (OTCQX ATBPF)
Antibe Reports Q3 2023 Interim Financial and Operating Results
– Recent animal data on otenaproxesul’s new formulation confirm rapid drug uptake and potential for effective pain management
– Targeting first clinical dose in calendar Q3 2023; Phase II top-line data within 12 months
– Ended quarter with $42.4 million in cash and equivalents, providing over two years of runway
TORONTO, February 15, 2023–(BUSINESS WIRE)–Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, has filed its financial and operating results for the fiscal quarter ended December 31, 2022.
1-31-2023 Coeptis Therapeutics, Inc. (OTC COEP)
Coeptis Therapeutics Enters into Sponsored Research Agreement with the University of Pittsburgh to Advance SNAP-CAR Development Program
Coeptis to collaborate with the University of Pittsburgh to expand pre-clinical development of SNAP-CAR T cells targeting HER2-positive cancers
WEXFORD, Pa., Jan. 31, 2023 /PRNewswire/ — Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (“Coeptis” or “the Company”), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced a sponsored research agreement with the University of Pittsburgh to advance pre-clinical development of SNAP-CAR T cells targeting HER2 as well as identify opportunities to expand the applicability of SNAP-CAR in oncology. SNAP-CAR, which Coeptis licensed from the University of Pittsburgh, is a multi-antigen chimeric antigen receptor T cell (CAR T) technology that can be adapted to different cancer indications, including hematologic and solid tumors.
Alternative Investments
Check out our latest commercial properties including an Amazing Private Island or Resort Development Property in Panama
3700 Acre Private Island in the Las Perlas Islands
7.4 Acre beachfront paradise for development or private retreat
Message me on Linkedin and check our latest commercial listings:
https://www.linkedin.com/in/carldilley/
Please subscribe to our newsletter to get ongoing Real Estate and Alternative Investing updates:
Black Swan Connection Newsletter Signup
| May 8, 2023 COMPANY QUOTES, LISTINGS RESEARCH AND NEWS Coeptis Therapeutics, Inc. Ecrid, Inc (ECDD) Profile Antibe Therapeutics, Inc (ATBPF) Profile 11/11/2018 News Can B Corp (CANB) Profile News Endurance Exploration Group, Ltd (EXPL) Profile 03-26/19 News International Food and Beverage Profile |
GARP with Yield and Excluding Falling Knives
April 28, 2023 by Herb Blank
GARP is an acronym used in the investment industry to connote “growth at reasonable prices.” Last week, we discussed the market size and style trends year-to-date and what our models expect to see for the year ahead. The bottom line is that both our predictive and valuation models thought the mega-cap-weighted ETFs, such as QQQ, IVV, XLK and IWF had gotten ahead of themselves in year-to-date gains and were now candidates to investigate for potentially trimming back positions. Conversely, we found the iShares Russell Small Cap ETF (IWF) to be the most attractive ETF that combines size and style. Beyond that, for potential price appreciation at a good value, we also liked the standard in small Cap, iShares Russell 2000 ETF (IWM) along with IWD, the iShares Russell 1000 Large Cap Value ETF.
Read complete report here
ValuEngine new strategies, Podcast introduction
ValuEngine Capital Management LLC (VECM) is pleased to announce the addition of Jordan Kimmel to the team as the new Chief Equity Strategist and portfolio manager. VECM is a Registered Investment Advisor (RIA) that invests based on the proprietary, quantitative research produced by ValuEngine Inc. It is an important partnership between two companies: ValuEngine conducts research, and ValuEngine Capital Management LLC actively trades client funds using this research.
VIEW JORDAN’S INTRODUCTORY PODCAST HERE
on www.ValuEngine.com
To subscribe to our bulletins and receive content whenever it is published, subscribe at our blog HERE
Want to learn more about ValuEngine? Our methods? Our history?
Check out our video presentation HERE
SMM Research Partners
Black Swan Research Coverage and Subscription Service
Click Here>>
Event Calendar Updates
Nothing new on the Conference front-stay tuned
dave@trickleresearch.com
Visit our homepage for up to the minute Financial News, Quotes and our Latest Black Swan Connection Newsletter
-SMM Distribution Update
Distribution (Reach)
SMM Global Twitter Acct (Impressions last 30 days) 520
SMM Global Facebook Page (Reach last-30 days) 6,462
SMM Linkedin Pages (contacts) 1,100
SMM Youtube Channel (followers) 6
SMM Instagram Page * (followers) 11
Direct Email * 220,000
Total 256,460